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Background. Evidence has shown that long-chain polyunsaturated fatty acids (LCPUFA), especially the 𝜔-3 fatty acids such as
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial for bone health and turnover. Objectives. This review
summarizes findings from both in vivo and in vitro studies and the effects of LC PUFA on bone metabolism, as well as the
relationship with the oxidative stress, the inflammatory process, and obesity.Results. Some studies in humans indicate that LCPUFA
can increase bone formation, affect peak bonemass in adolescents, and reduce bone loss.However, the cellularmechanisms of action
of the LCPUFA are complex and involve modulation of fatty acid metabolites such as prostaglandins, resolvins and protectins,
several signaling pathways, cytokines, and growth factors, although in certain aspects there is still some controversy. LCPUFA
affect receptor activator of nuclear factor 𝜅𝛽 (RANK), a receptor found on the osteoclast, causing bone resorption, which controls
osteoclast formation. Conclusions. Since fatty acids are an endogenous source of reactive oxygen species, free radicals alter the
process of bone turnover; however, although there are clinical evidences linking bone metabolism and dietary lipids, more clinical
trials are necessary to prove whether 𝜔-3 PUFA supplementation plays a major role in bone health.
1. Introduction
Omega-3 polyunsaturated fatty acids (𝜔-3 PUFA) are a
group of essential fatty acids (FA), and they cannot be
synthesized in sufficient amounts for health, therefore, they
are components of the human diet [1]. Alpha-linolenic acid
(ALA), eicosapentaenoic acid (EPA), and docosahexaenoic
acid (DHA) are three important omega-3 fatty acids. ALA is
the omega-3 fatty acid ingested in greatest amount in a typical
diet and is found in leafy vegetables, walnuts, soybeans, and
seed and vegetable oils. Sources of EPA and DHA are fatty
fish such as salmon, fish oil supplements, or the conversion
of ingested alpha-linolenic acid to DHA or EPA, although
evidence reports that the conversion rate is low [2]. EPA
and DHA have many potential health benefits, reducing risk
of coronary heart disease [3], and potential benefits in the
prevention and treatment of other cardiovascular disorders,
some forms of mental illness, inflammatory disorders, and
insulin resistance [1, 4].
Hence, it has been suggested that 𝜔-3 PUFA play an
important role in bone metabolism and may represent a
useful nonpharmacological way of ameliorating bone loss
and risk of osteoporosis. 𝜔-3 is precursor for several potent
regulatory eicosanoids involved in bone metabolism includ-
ing PG and leukotrienes. Thereby, 𝜔-3 PUFA can inhibit
the production of these inflammatory cytokines such as IL-
1, IL-6, and TNF-𝛼, which provide an important stimulus
for osteoclastic bone resorption, and suppression of the
production of these cytokines by 𝜔-3 PUFAmay inhibit bone
resorption and prevent bone loss [5].
To date few studies have examined the role of these essen-
tial fatty acids, particularly 𝜔-3 PUFA in skeletal metabolism
in humans, and the findings show controversy [6]. One
possible explanation for these conflicting observations is that
2 The Scientific World Journal
𝜔-3 PUFAhave relativelymodest effects on bonemetabolism,
making it difficult to detect changes after supplementation,
and this may be a particular issue for indices such as bone
mass density (BMD) which are relatively insensitive to short-
term change as compared with biochemical bone turnover
markers [7]. The differences in 𝜔-3 PUFA supplementation
alsomay be crucial:𝛼-linolenic acids like EPA andDHAor all
𝜔-3 PUFA in general are thought to have many different roles
and actions in the body, which may or may not be linked to
skeletal metabolism. 𝜔-3 PUFA dose, supplement intake, and
duration may also have different effects [8].
2. Bone Metabolism
Bone remodeling is regulated by controlling osteoblast (bone-
forming cells) and osteoclast (bone-resorption cells) cell
number and activity. Osteoclastogenesis is in large part regu-
lated by a triad of proteins consisting of a ligand, receptor-
activated nuclear kappa-𝛽 ligand (RANKL), its receptor,
RANK, and a decoy receptor, osteoprotegerin (OPG). RANK
is a membrane-bound protein expressed on osteoclast pre-
cursors and mature osteoclasts [9]. RANK-L exists in both
a membrane-bound and soluble form and is produced
by a range of cells including osteoblasts and activated T
cells. OPG is a soluble protein secreted by different cells,
including osteoblasts. Binding of RANK-L to RANK leads
to osteoclastogenesis and inhibits osteoclast apoptosis [10].
Binding of RANK-L to OPG prevents RANK-L/RANK-
induced osteoclastogenesis, and increasedOPGprotein levels
promote a rapid reduction in osteoclast number. Moreover,
the balance between RANK, RANK-L, and OPG is a major
factor controlling osteoclast number [8].
Bone remodeling occurs within the skeleton and is
activated in response to mechanical strain. Osteocytes are
“mechanosensing” specialized cells that reside in bone
matrix. They detect mechanical strain and initiate signaling
pathways, promoting both osteoclastogenesis and osteoblas-
togenesis [8]. The role of lipid mediators in the signaling
pathway is critical. In few seconds aftermechanical loading of
bone, the lipid mediator prostaglandin E2 (PGE2) is released
by osteocytes and mature osteoblasts [11]. Phospholipase-
mediated membrane releases fatty acids; mainly arachidonic
acid (AA, 20:4n-6), the substrate for PGE2 synthesis, and
expression of the inducible form of cyclooxygenase (COX),
COX-2, which oxidizes AA to PGE2, are upregulated as an
early response [12]. PGE2 promotes osteoclastogenesis by
stimulating expression of both RANK-L and RANK and
inhibiting expression of OPG. PGE2 also activates the Wnt
signaling pathway and promotes core binding factor 𝛼-1
(cbfa-1) and insulin-like growth factor 1 (IGF-1) expression,
thus stimulating osteoblastogenesis [13]. PGE2 is potent
modulators of bone remodeling, affecting bone resorption,
by stimulating osteoclastogenesis through RANKL. Both
processes, formation and resorption, are related to PGE2, and
its effects on bone may be dose-dependent. At high levels,
PGE2 suppresses osteoblast and promotes differentiation and
bone resorption by osteoclasts via RANKL, whereas low
levels stimulate bone formation by osteoblasts [14].
Although the importance of AA and PGE2 in regulating
bone remodeling is well established, the involvement of
LCPUFA in the control of bone metabolism may be much
more extensive than being currently known.
3. Physiological Factors Affecting Bone
Metabolism
3.1. Oxidative Stress and Bone Remodeling. Reactive oxygen
species (ROS) are oxygen-containing molecules, which are
produced during normal metabolism. Overproduction of
ROS induces an imbalance between antioxidants and proox-
idants in cells and tissues causing oxidative stress, which has
been related to ageing, tissue inflammation, and degeneration
[15].
According to evidence, there is a link between bone
metabolism and redox balance regulation, indicating that
ROS may play a major role in osteoporosis in part by inhibit-
ing osteoblast generation. ROS are also involved in cartilage
homeostasis and degradation, in particular with respect to
the development of osteoarthritis (OA). Rheumatoid arthritis
(RA) is an autoimmune disease characterized by chronic
inflammation which causes joint destruction. Although, RA
is not generally recognized as a disease of oxidative stress, it
has been suggested that the level of ROS in patients with RA is
higher than in healthy subjects. Researches have also reported
that ROS could be a key modulator of bone cell function
and play a role mediating intracellular signaling [16]. Thus,
the ultimate mechanism behind ROS contribution to bone
metabolism is still controversial.
Physical activity plays role in bone health; in this way, it
is recommended as a treatment for the prevention of bone
loss. Exercise influences the cellular homeostasis, and some in
vitro studies have reported that mechanical loading increased
the oxidative stress in chondrocytres and osteoblast-like
cells. In contrast, exercise can lead to an increase in some
antioxidants in bone as well as cartilage [17, 18].
During normal physiological conditions ROS are pro-
duced at low levels and removed by endogenous antioxidant
systems. Their “steady-state” concentrations are determined
by the balance between their rates of production and removal
by various antioxidants [15]. Mitochondria are considered as
the main source of intracellular ROS, but other enzymatic
systems, such as NADPH oxidases, cytochrome P-450, cyclo-
oxygenase, aldehyde oxidase, dihydroorotate dehydrogenase,
tryptophan dioxygenase, nitric oxide synthase, and xanthine
oxidase, contribute also to ROS production. Furthermore,
both aging and oestrogen deficiency increase the generation
of ROS, and there is evidence to suggest that adverse effects
of oestrogen loss on bone may be prevented by antioxidants.
Hence, ROS are also produced in response to external stimuli,
such as growth factors, inflammatory cytokines, chemother-
apeutics, environmental toxins, ultraviolet light, or ionizing
radiation [18].
Enzymatic antioxidant defenses include superoxide dis-
mutase (SOD), catalase (CAT), glutathione peroxidase (GPx),
and glutathione reductase (GR). These can be modified by
exercise, nutrition, and aging. Nonenzymatic antioxidants
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include a variety of quenchers such as ascorbic acid, 𝛼-
tocopherol, carotenoids, flavonoids, thiols which include
glutathione (GSH), ubiquinone Q 10, uric acid, bilirubin,
ferritin, and micronutrients which act as enzymatic cofactors
[18].
At the molecular level, cellular stress response pathways
are controlled by four categories of molecules and transcrip-
tional regulators: insulin/IGF-1 signalling, sirtuins, target
of rapamycin, and AMP-activated protein kinase-dependent
pathways. All these pathways have one molecular target
in common, named forkhead box O (FoxO) transcription
factors, a family of transcription factors that comprises four
members: FoxO1/FKHR, FoxO3/FKHRL1, FoxO4/AFX, and
FoxO6. FoxOs play an important role in bone biology by
enabling the maintenance of a physiologically appropriate
lifespan of mature osteoblasts through their defense activities
or via modulating the activity of other transcription factors
such as 𝛽-catenin [19]. The antioxidant defense provided
by FOxOs is overtaken by high oxidative stress and/or
oxidative stress activated pathways that interfere with the
activity of FoxOs. ROS play a double role as both deleterious
and beneficial species, because they can be either harmful
or beneficial to living systems, particularly by playing a
physiological role in intracellular signalling and regulation
as secondary messengers. Nevertheless, signalling via ROS
is harmful as overproduction of reactive signal molecules
may be destructive. A large variety of diseases are known to
involve oxidative stress, including bone disease [18].
Bone remodeling is performed by osteoblasts and osteo-
clasts. Tipping this balance in favour of the osteoclasts leads
to pathological bone resorption, as seen in bone diseases.
ROS are involved in apoptosis of osteoblasts and osteocytes
and osteoclastogenesis and in this way in bone resorption
[20]. Actually, ROS have a spectrum of responses ranging
from proliferation to growth or differentiation arrest to
cell death by activating numerous signalling pathways, heat
shock factor (HSF), and MAPKs including extracellular
signal-regulated kinases (ERKs), c-Jun-N terminal kinase
(JNK), p38 MAPK, and ERK5. The osteoprotegerin (OPG),
the receptor activator of NF-𝜅𝛽 (RANK), and the receptor
activator of NF-𝜅𝛽 ligand (RANKL) play also a crucial role
in bone remodeling and functions as a pivotal molecular link
for osteoblast and osteoclast coupling [21] (Figure 1).
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role in osteoclast function and differentiation. ROS increases
osteoclast number and resorption by stimulatingRANKLand
TNF-𝛼 expression through ERK and NF-𝜅𝛽 activation. TNF-
𝛼 not only causes cell damage but also inhibits SOD1 and
SOD3 [22].
RANKL activates mature osteoclasts and mediates osteo-
clastogenesis. It binds to its receptor, RANK, promoting
their differentiation into mature osteoclasts. OPG acts as
a decoy receptor for RANKL, avoiding it from binding to
and activating RANK. Abnormalities of the RANK-RANKL-
OPG system with an unbalanced increase in RANKL activ-
ity have been implicated in the pathogenesis of various
skeletal diseases, including osteoporosis and bone disease
secondary inflammation. The increased osteoclastic activity











Figure 1: ROS-activated signalling pathways affecting the genesis
of osteoblasts and osteoclasts. In osteoclast precursors, RANKL-
induced activation of RANK stimulates ROS production, which
is important for osteoclastogenesis. ROS-induced bone resorption
occurs through the modulation of kinases and transcription factor
activities in both osteoclasts and osteoblasts.
inhibit SOD and GPx activities with concomitant bone
destruction [23].
Osteoblasts can produce antioxidants to protect against
ROS, such as GPx, as well as transforming growth factor-𝛽
(TGF-𝛽), which is implicated in reduction of bone resorption.





intracellular ROS and suppressed the differentiation process
of osteoblasts, manifested by a reduction of differentia-
tion markers including type 1 collagen, ALP, and colony-





xanthine/xanthine oxidase-induced oxidative stress is also
able to inhibit bone cell differentiation of preosteoblas-
tic cell line (MC3T3-E1) and of a marrow stromal cell
line (M210B4) that undergoes osteoblastic differentiation.
Oestrogens antagonize ROS-induced osteoblast apoptosis
and the prosurvival effects of receptor activator of RANKL
on osteoclasts and decrease oxidative stress. It has been
suggested that elucidation of these mechanisms provides a
paradigm shift from the “oestrogen-centric” account of the
pathogenesis of involutional osteoporosis to one in which
age-related mechanisms intrinsic to bone are central to the
disease process [18, 24].
In response to stress, DNA-damage repair genes that
counteract the adverse effects of ROS and FoxOs upregu-
late enzymatic scavengers, therefore representing an indis-
pensable homeostatic mechanism for skeletal health. This
response involves upregulation of the expression of the









intowater, and the growth arrest andDNA-damage-inducible
GADD45 [25]. Furthermore, FoxOs may control the gen-
eration of new osteoblasts from their mesenchymal stem
cell progenitors by modulating their proliferation and/or
differentiation through their antioxidant properties. Some
studies have found a diminution in antioxidant activity
in patients with osteoporosis. GPx1, the enzyme primarily
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highly expressed in osteoclasts, and its expression in bone
marrow macrophages by RANKL and in osteoclasts by
oestrogens. Overexpression of GPx in osteoclast progeni-
tors abolishes osteoclast formation and suppresses RANKL-
induced NF-𝜅𝛽 activation and increased resistance to oxida-
tion [26]. Oxidative stress acted as an independent risk factor
for osteoporosis linked to the increase of SOD/GPX ratio.
Hence, the imbalance propitiated by greater SOD activity





leading to greater oxidative stress [18].
3.2. Inflammation and Bone Remodeling. Human studies
have reported wide evidence to implicate the crucial role of
osteoclasts in the pathogenesis of bone erosions in patients
with rheumatoid arthritis (RA). The role of osteoclasts in
bone resorption has been found to be also crucial in other
inflammatory arthritis.
Ritchlin et al. (2003) [27] have found that patients with
psoriatic arthritis, who have characteristically elevated serum
TNF-𝛼 levels, have a significant increase in the osteoclast
precursor cell pool within the peripheral blood mononuclear
cells populations that in turn are correlated with the extent
of bone destruction. The fact that osteoclasts are largely
responsible for focal bone erosions has increased efforts in the
researchers to elucidate the exact role played by a number of
cytokines and inflammatory mediators that has the capacity
to induce the recruitment, differentiation, and activation of
these osteoclast [28].
RANKL plays a role in controlling osteoclastogenesis.
Inflamed synovial tissue produces a variety of other cytokines
and hormones that can also influence osteoclastogenic activ-
ity. These factors include interleukin-1𝛼 (IL-1𝛼), IL-1𝛽, TNF-
𝛼, IL-6, macrophage colony stimulating factor (M-CSF), IL-
17, and parathyroid hormone related hormone related peptide
(PTHrP) [28].
The role of these cytokines in bone erosions and in
inflammation reports further evidence to a link between
immune system activation and bone resorption. When the
function of OPG/RANK/RANKL in bone remodeling was
perceived, it was hypothesized that RANKL may be of
major pathophysiological importance in the bone and joint
destruction observed in inflammatory RA [29].
According to some studies, activated T cells from the
RA synovium and synovial fibroblasts produce RANKL [29].
Indeed it is currently known that activated T cells, which play
a central role in the pathogenesis of RA,may contribute to the
osteoclast-mediated bone resorption via RANKL expression
(Figure 2).
In bone destruction associated with RA, IL-17-producing
helper T cells (TH17) play a major role by inducing receptor
activator of nuclear factor-𝜅𝛽 ligand (RANKL). RANKL
stimulates osteoclastogenesis through nuclear factor of acti-
vated T-cells cytoplasmic 1 (NFATc1), which is a crucial
regulator of immune response [30]. In addition to cellular
interactions via cytokines, the immune and skeletal sys-
tems share various molecular pathways, including mem-






















Figure 2:The OPG/RANK/RANKL system and osteoclastogenesis.
3.3. Obesity and Bone Remodeling. The relationship between
obesity and bone is complex and continues being an active
research area. Current data from epidemiological and animal
studies have shown that fat accumulation may interfere with
bonemass. Obesity possibly affects bonemetabolism through
several mechanisms. Both adipocytes and osteoblasts are
derived from a common multipotential mesenchymal stem
cell, thereby obesity may increase adipocyte differentiation
and fat accumulation while decreasing osteoblast differentia-
tion and bone formation. Obesity is also in relation to chronic
inflammation. The increased circulating and tissue proin-
flammatory cytokines in obesity may stimulate osteoclast
activity and bone resorption through modifying the receptor
activator of NF-𝜅𝛽 (RANK)/RANK ligand/osteoprotegerin
pathway. Moreover, the excessive secretion of leptin and/or
decreased production of adiponectin by adipocytes in obe-
sity may either directly affect bone formation or indirectly
affect bone resorption through upregulated proinflammatory
cytokine production. High-fat intake may be detrimental to
intestinal calcium absorption and therefore decrease calcium
availability for bone formation [31].
A growing evidence supports that obesity and bone
metabolism are linked. Firstly, both osteoblasts (bone form-
ing cells) and adipocytes (energy storage cells) are derived
from a commonmesenchymal stem cell and agents inhibiting
adipogenesis stimulated osteoblast differentiation [32] and
vice versa, those inhibiting osteoblastogenesis increased adi-
pogenesis. Second, decreased bone marrow osteoblastogene-
sis with aging is usually accompanied with increased marrow
adipogenesis. Third, chronic use of steroid hormone, such as
glucocorticoid, leads to obesity accompanied by rapid bone
loss. And fourth, both obesity and osteoporosis are associated
with increased production of proinflammatory cytokines and
elevated oxidative stress [33].
Obesity is traditionally thought to be beneficial to bone
and, hence protecting against osteoporosis. Mechanical load-
ing stimulates bone formation by decreasing apoptosis and
increasing proliferation and differentiation of osteoblasts and
osteocytes through the Wnt/𝛽-catenin signaling pathway
[34]. But excessive fat mass may not protect from osteoporo-
sis and in fact, and increased fat mass is associated with low
total bone mineral density and total bone mineral content
[31].
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According to available literature to date, obesity seems to
affect bonemetabolism through severalmechanisms.Obesity
may decrease bone formation (osteoblastogenesis) while
increasing adipogenesis because adipocyte and osteoblasts
are derived from a common multipotential mesenchymal
stem cell. While research with obese animal model has estab-
lished the negative effects of adiposity on bone metabolism,
studies with human subjects continue to be controversial [31].
Obesity may increase bone resorption through upreg-
ulating proinflammatory cytokines such as IL-6 and TNF-
𝛼. These proinflammatory cytokines are capable of stim-
ulating osteoclast activity through the regulation of the
RANKL/RANK/OPG pathway. Obesity is in relation to
degenerative and inflammatory musculoskeletal system.
Bone marrow adipocytes may also directly regulate the
osteoclast progenitors (hematopoietic cells) [31, 35].
Obesity appears to affect bone metabolism directly or
indirectly through adipocyte-derived cytokines such as leptin
and adiponectin. Obesity is linked with significant increase
in serum leptin and decrease in adiponectin. The action
of leptin on bone may be complex and both positive and
negative effects have been reported [36]. Its action seems to
depend on current leptin status and the mode of the action.
Obese subjects have low serum adiponectin concentrations
as compared to those normal subjects. Increased secretion
of leptin (and/or decreased production of adiponectin) by
adipocytes may also contribute to macrophage accumulation
by simulating transport of macrophages to adipose tissue
and promoting adhesion of macrophages to endothelial cells,
respectively [37].
Based on current data obesity is detrimental to bone
health. The decreased bone mass with obesity may be due to
increasedmarrow adipogenesis at the expense of osteoblasto-
genesis, increased osteoclastogenesis due to the upregulation
of proinflammatory cytokines, excessive leptin secretion or
reduced adiponectin production [31].
In fact, a high-fat diet, a common cause of obesity, has
been reported to interfere with intestinal calcium absorption.
Free fatty acids can form unabsorbable calcium soaps and
contribute to low calcium absorption. Increased body weight
associated with obesity may counteract the detrimental
effects of obesity on bone metabolism. It is well known
that body weight or body mass index (BMI) is positively
correlated with bone mineral density or bone mass [38] and
low body weight or BMI is a risk factor for low bone mass
and increased bone loss in humans. Although some studies
indicate that the positive effects of body weight could not
completely compensate the detrimental effects of obesity on
bone, at least in obese animal models [31].
4. Nutrition in Bone Remodeling Process
Diet can be modified for the maintenance and development
of bone mass. The most relevant nutrients to bone health are
calcium and phosphorus because they compose roughly 80%
to 90%of themineral content of bone hydroxyapatite; protein
is essential because it is incorporated into the organic matrix
of bone for collagen structure upon which mineralization
occurs; and otherminerals, trace elements, and vitamins (e.g.,
vitamins D and K) are also crucial in carrying out metabolic
processes and reactions in bone [29, 30]. Other benefits on
bone metabolism derives from bioactive components found
basically in vegetables but also some herbs and fruit. Phy-
tochemicals, antioxidants, and other bioactive compounds
influence bone metabolism through a variety of mechanisms
manly in reducing oxidative stress and inflammation [37].
Data from the Framingham study [31] concluded that
participants who had a diet based on fruit, vegetables,
milk, and cereals had a significantly higher bone mass than
those whose diet was characterized by high consumption
of snacks, pizza, and/or high consumption of meat, bread,
and potatoes. Nakashima and Takayanagi [30] evaluated
associations between dietary patterns and bone mineral
density (BMD) in Japanese farmwomen and found that a
“healthy” pattern, described by high intakes of green and
dark yellow vegetables, mushrooms, fish and shellfish, and
fruit, was positively related to BMD. Furthermore, the effect
of vegetarian dietary patterns on skeletal health has been
studied; lacto-ovo vegetarians appear to have normal bone
mass when compared with omnivores, whereas a more
recent review reported that the scientific findings support
the hypothesis that vegans do have lower BMD than their
nonvegan counterparts [29, 32].
An adherence to a Mediterranean diet pattern is not
associated with indices of bone mass (in a sample of adult
women), whereas adherence to a dietary pattern close to
the Mediterranean diet, that is, high consumption in plant
foods and olive oil, low in meat and dairy products, and with
moderate intake of alcohol, is positively related to bone mass
and total body bone mineral content, suggesting potential
bone-preserving properties of this pattern throughout adult
life [29].
It is known that the intake of fruit and vegetables is pos-
itively associated with bone health by provision of essential
micronutrients for bone formation, buffer precursors which
reduce acid load, and phytochemicals affecting inflammation
and oxidative stress.
The beneficial effect is because of the provision of
micronutrients magnesium, potassium, calcium, vitamins
A, C, E, and K, and potentially a lower dietary acid load
conferred by the fruit and vegetables food group [33]. Typ-
ical diets are acidic because predominantly acid (hydrogen
ions) rather than base (bicarbonate) is created during the
metabolism of the daily food intake. Acid forming grains and
high protein food derived from animal origin (meat, fish,
and eggs) contain sulphur-based amino acids, methionine,
and cysteine which create acid when metabolized. Alkaline
forming foods contain potassium salts which can be broken
down to make alkaline buffers [34]. Vegetables and fruit are
considered alkaline because of their high mineral content in
the form of salts of organic acids. The salts, predominantly
potassium based but also calcium and magnesium, generate
bicarbonate to balance the acid produced from the rest of the
diet [35].
The low grade metabolic acidosis induced by the modern
diet is exacerbated during ageing when renal function begins
to decline requiring the body’s skeletal reserves to be called
upon to relinquish bicarbonate to produce alkaline buffers
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needed to continuously balance the acid load.Therefore bone
mass is gradually and indefinitely reduced after the age of
30 years, accelerating at menopause to lower bone strength
and mineral density. Fruit/vegetables influence on acid-base
balance is crucial, being the unique dietary source of alkaline
precursor constituents, so it is important reason to increase
consumption to avoid bone loss during ageing [35, 36].
An increase in vegetable and fruit consumption to
≥9 servings/day will reduce the estimated net endogenous
acid production by approximately 20mEq/day and result in
reduction in bonemarkers of resorptionC telopeptide of type
1 collagen (CTx) and bone formationmarker Procollagen 1N-
terminal peptide (P1NP) in postmenopausal women. Those
women who include 4-5 servings of vegetables, herbs, and
fruit featured bone resorption inhibitory properties (BRIPs)
and half of the 9 servings/day will reduce resorption marker
CTx by a greater amount. It is also hypothesised that this
increase in fruit and vegetable intake will significantly affect
inflammatory and metabolic markers including C-reactive
protein (CRP) adiponectin, interleukin 6 (IL-6), interleukin
10 (IL10), tumour necrosis factor (TNF-𝛼), triglycerides,
cholesterol, fibrinogen, and plasminogen activator inhibitor-1
(PAI-1) [35].
Furthermore, selenium is an essential nutrient that plays
an important role in bone status. That role is likely to
involve the functions of selenoproteins. Many selenoproteins
are antioxidant enzymes that participate in maintaining
cell redox balance, which is important in the regulation
of inflammation and bone cell proliferation/differentiation.
Selenium (Se) may play additional cellular roles, particu-
larly at supranutritional doses, that is, doses greater than
those required for maximal selenoprotein expression. These
include the induction of cell cycle arrest, apoptosis, immune
function, and the prevention of the bone resorption through
the inactivation of osteoclasts. These cellular activities of Se
at both nutritional and supranutritional doses may partially
account for the potential protection against rheumatoid
arthritis, osteoarthritis, osteoporosis, and ROS produced by
osteoclasts during bone remodeling [39, 40].
In a recent study [41], the authors have investigated
that the effect of various carotenoids (carotene and xantho-
phylls including beta- (𝛽-) cryptoxanthin, lutein, lycopene,
b-carotene, astaxanthin, and rutin), and 𝛽-cryptoxanthin,
which is abundant in Satsuma mandarin orange (Citrus
unshiu Marc.), has a stimulatory effect on bone calcification
in vitro.𝛽-cryptoxanthin has stimulatory effects on osteoblas-
tic bone formation and inhibitory effects on osteoclastic
bone resorption in vitro, thereby increasing bone mass.
𝛽-cryptoxanthin has an effect on the gene expression of
various proteins that are related osteoblastic bone formation
and osteoclastic bone resorption in vitro. The intake of 𝛽-
cryptoxanthin may have a preventive effect on bone loss
in animal models for osteoporosis and in healthy human
or postmenopausal women. In addition, the role of 𝛽-
cryptoxanthin in bone health has been also shown in human
subjects with epidemiological studies. The supplemental
intake with the combination of 𝛽-cryptoxanthin and other
nutritional factors may have a potential effect in the main-
taining of bone health and decrease in bone loss [38].
4.1. Effect of 𝜔-3 Fatty Acids on Bone Remodeling. Dietary fat
may influence bone health. Long-chain polyunsaturated fatty
acids (LCPUFAs), specially the omega-3 (𝜔-3) fatty acids such
as EPA andDHA, are beneficial for bonemetabolism. Several
studies in humans have reported that LCPUFAs can increase
bone formation, affecting peak bone mass in adolescents and
reducing bone loss [14].
However, the cellular mechanisms of action of the LCP-
UFAs are complex and involve modulation of fatty acid
metabolites such as prostaglandins, resolvins and protectins,
cytokines, growth factors, and some other molecular signal-
ing pathways. There are several mechanisms by which 𝜔-3
PUFAs can regulate bone metabolism, including a decrease
in the release of prostaglandin E2 (PGE2) and, in the most
important osteoclast differentiation factor, receptor-activated
nuclear kappa-𝛽 ligand (RANKL). Furthermore, 𝜔-3 may
modulate the number of proinflammatory cytokines, increas-
ing production of IGF1 and improving calcium accretion in
bone [14, 39].
The prostaglandins (PGs), produced from essential fatty
acid precursors (20:4 𝜔-6 and 20:5 𝜔-3) in osteogenic cells,
regulate both bone formation and bone resorption. In sup-
port of the relationships between dietary PUFA, PGs, and
bone metabolism, Li et al. (1999) [40] reported that dietary
lipids modulated ex vivo bone PGE2 production and the
concentration of IGF-I in bone tissues and led to altered
bone formation rates in growing chicks and rats. In these
experiments, animals given long-chain 𝜔-3 fatty acids tended
to show an increased rate of bone formation, suggesting a
stimulatory effect on osteoblastic activity.The favorable effect
of 𝜔-3 fatty acids on bone turnover in growing animals is
supported by the observation of reduced bone mineral loss
in ovariectomized rats supplemented with eicosapentaenoic
acid (EPA 20:5 𝜔-3). The bone-sparing effect of 20:5 𝜔-3 may
be associated with diminished bone resorption or increased
bone formation. In addition, the action of 𝜔-6 fatty acids
(linoleic acid) with long-chain 𝜔-3 fatty acids can benefit
bone modeling [42].
In this sense, dietary intake of essential fatty acids plays
a crucial role in the cell membrane and the production of
various cytokines by inflammatory cells. The 𝜔-6 fatty acids,
especially arachidonic acid (AA), are the primary source of
the 𝜔-6 eicosanoids that are produced from the oxygenation
of AA by cyclooxygenase, lipoxygenase, and epoxygenase
enzymes to produce prostaglandins, leukotrienes, lipoxins,
and P-450 compounds. The dietary long-chain 𝜔-3 fatty
acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) partially replace the 𝜔-6 fatty acids, particularly AA,
in the membranes of platelets, erythrocytes, neutrophils,
monocytes, and liver cells. This leads to a change in the
ratio of 𝜔-6/𝜔-3 fatty acids in membranes and a change in
their function which can decrease the production of IL-1,
IL-6, and TNF-𝛼. The modulatory effect of essential fatty
acids on cytokines plays a pivotal role in the pathogenesis of
osteoporosis [43, 44] (Figure 3).
According to Casado-Dı́az et al. [45] consumption of
omega-3 may protect against osteoporosis because they may
inhibit osteoclastogenesis. However, with aging, mesenchy-
mal stem cells (MSC) in bone marrow are increasingly












Figure 3: The relationship between cytokines and osteoclastogene-
sis. IL-1: interleukine-1; IL-6: interleukine-6; TNF-𝛼: tumor necrosis
factor-𝛼.
differentiated into adipocytes, reducing the number of
osteoblasts. Products derived from omega-6 and omega-3
metabolism may affect MSC differentiation into osteoblasts
and adipocytes. Indeed, MSC precursors may differentiate
into adipocytes instead of into osteoblasts, in a process
which is accelerated with aging. According to the ratio of
omega-6/omega-3 consumed, certain types of metabolites
will be produced, modifying some physiological processes
and consequently the susceptibility or resistance to the
appearance of different pathologies. In general, physiological
processes involving metabolites derived from these two types
of polyunsaturated fatty acids are in opposition to each other.
So eicosanoids derived from omega-6 are considered mainly
proinflammatory, while those derived fromomega-3 are anti-
inflammatory [45, 46].
The healthy recommended ratio of omega-6/omega-3
fatty acids is approximately 1 : 1; however actual estimations
indicate that it is in fact much higher between 15 : 1 and
16.7 : 1. According to the evidence, a reduction in the omega-
6/omega-3 proportion decreases the risk of suffering car-
diovascular pathologies, tumors, and other chronic diseases,
including osteoporosis [43]. It is hypothesized that these
polyunsaturated fatty acids also act on bone formation,
because the products of the metabolism of omega-6 and
omega-3 fatty acids can act on precursor cells of osteoblast
and adipocytes [45].
Various in vivo and in vitro studies have been carried
out to study the possible incidence of omega-3 fatty acids
in bone metabolism. Several lines of evidence have shown
that the anti-inflammatory effect of omega-3 can lower the
osteoclastic activity and thus reduce bone resorption [47].
A diet rich in omega-6 fatty acids which rises omega-
6/omega-3 ratio seems to cause not only cardiovascular
problems but also an increase in the adiposity of the
bone marrow, by enhancing the adipogenic differentiation
of MSC, inhibiting their differentiation into osteoblasts.
Consequently, this could have a negative impact on bone
metabolism. Furthermore, a diet with a suitable proportion
of omega-6/omega-3 fatty acids appears to avoid pathologies
in the bone health associated with aging, such as osteoporosis
[43].This is because omega-3 fatty acids do not exert a strong
adipogenesis induction capacity as the one of the omega-6
fatty acids, thus allowing the osteoblastogenesis. That fact,
together with their inhibitory effect on osteoclastogenesis,
may improve the maintenance of the bone mineral mass.
The NHANES III data has established the correlation
between dietary fat and hip BMD (bone mineral density)
in 14,850 men and women. There was no significant asso-
ciation between total fat intake and BMD at any sites of
the analysis. On the other hand, saturated fat intake was
negatively associated with BMD in the femoral neck across all
subjects, and the greatest effect was observed inmen younger
than 50 years of age. This indicates the probability of more
vulnerability of men to the undesirable effects of saturated fat
on bone density [48].This study is in agreement with another
study which was conducted with 20 men and 3 women
using a controlled feeding protocol. Significant reduction
was reported in N-telopeptide (NTx) (a key marker of bone
resorption) when the subjects consumed diet containing∼8%
saturated fatty acid (SFAs) and ∼17% PUFAs compared with
a diet containing ∼13% SFAs and ∼9% PUFAs [49].
In other research, it was investigated the role of fatty acids
on bone accumulation and attainment of peak bone mass
in young men. In this cohort study 78 healthy young men
were enrolled. BMD of the total body, hip, and spine was
measured at baseline and at 22 and 24 years of age. Fatty-acid
concentration was measured at 22 years of age. The results
showed that 𝜔-3 fatty acids, especially DHA, are positively
associated with bone mineral accumulation and therefore
with peak BMD in young men [50]. In the first controlled
feeding study in humans, the effect of dietary plant-derived
𝜔-3 PUFAs on bone turnover was assessed. In this study, 23
subjects consumed each diet in a randomized, three-period
crossover design. Each diet consisted of different amounts
of saturated and unsaturated fatty acids. Bone turnover was
assessed by the differences in serum concentrations of NTx
and BSAP at baseline and six weeks later. There was no
change in the levels of BSAP across the three groups.TheNTx
levels showed significant changes and positively correlated
with the proinflammatory cytokine TNF-𝛼 in all the groups.
The authors concluded that plant sources of dietary 𝜔-3
PUFAs may have a protective effect on bone metabolism via
a decrease in bone resorption in the presence of consistent
levels of bone formation [49, 51].
4.1.1. 𝜔-3 Fatty Acids and Oxidative Stress. It is well known
that reactive oxygen species (ROS) and oxidative stress are
one of the main factors in the regulation of bone status
[52]. The role of ROS in bone metabolism is unique and
dual due to their effect under physiological and pathological
conditions. Under physiological conditions, the production
of ROS by osteoclasts assists in accelerating destruction of
calcified tissue and hence assists in bone remodeling [53, 54].
Although enhanced osteoclastic activity and increased
production of ROS are linked in many skeletal pathologies,
it remains to be unclear whether increased ROS production
overwhelms the antioxidant defenses, in subjects with oxida-
tive stress.
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Osteoclasts chisel away at older bone, opening tiny holes
that will be refilled by osteoblasts. The chisel molecule is
a superoxide radical, which is one of the highest reactive
oxygen species (ROS). ROS also play a specific role in
sculpting or remodeling of bone. The role of antioxidants in
controlling ROS formation is also well established. In this
way, decreased activity of the antioxidant enzymes, SOD,
and GSH-PX showed a defense mechanism that appears to
have been overtaken in reducing the increased superoxide
production by the osteoclasts [53].
A long-term study reported that 𝜔-3 FA reduce per-
oxidation of lipids (reducing oxidative stress) [55]. Acute
enrichment of plasma with 𝜔-3 FA did not increase lipid-
mediated insulin resistance; neither was oxidative stress
reduced, therefore, an inhibitory effect on FA oxidation is
possible.
The influence of 𝜔-3 fatty acids on lipid peroxidation
in vivo depends on the balance of oxidative stress and
induced antioxidative enzymes, but the overall effect appears
contradictory.This is probably due to the different doses of𝜔-
3 fatty acids used, different amounts of antioxidants supplied,
and different methods used to quantify the oxidative stress
in previous studies [56]. Thereby, when the level of F2-
isoprostane was used as a criterion, all studies demonstrated
no enhancement of in vivo oxidant stress after 𝜔-3 fatty acid
supplementation [57, 58].
The susceptibility of fatty acids to oxidation is known to
be directly dependent on their degree of unsaturation. Never-
theless, some in vitro [59] and in vivo [58, 60] studies suggest
that the relation between chemical structure and suscepti-
bility to oxidation is not as straightforward as hypothesized
from theoretical viewpoints. Some evidence indicates that
kinetics of fatty acid oxidation depend on the compartment
in which they react with oxidants: aqueous environments
(such as those at the cell membrane/plasma and cytosol/cell
membrane interfaces) yield different oxidation profiles than
the organic ones [61].
Based on evidence, the higher number of unsaturations
present in 𝜔-3 long-chain fatty acids has been postulated
to enhance lipid peroxidation. However, the influence of
fish oil supplementation on some indicators of oxidative
stress was not consistent, partly because 𝜔-3 fatty acids
also enhanced the activities and expression of antioxidant
enzymes, such as catalase, glutathione peroxidase, and super-
oxide dismutase [56, 62]. For example, when individual fatty
acids are oxidized in an aqueous environment, the generation
of peroxidation products does not reflect their degree of
unsaturation [63]. Furthermore, Mazière et al. (1998) [61]
compared the effects of omega-6 and omega-3 fatty acids,
incorporated into endothelial cells, with respect to cellular
ability to oxidize LDL.They reported that omega-3 fatty acids
lowered TBARS production, superoxide anion secretion, and
LDL peroxidation compared with omega-6. Their interpre-
tation was that omega-3 was less efficiently incorporated
into cellular lipids, even though after a similar percentage
of PUFA incorporation, omega-3 fatty acids still induced a
less marked increase in LDL modification as compared with
omega-6. One explanation proposed by the authors was that
the omega-3 series, due to the position of their unsaturations,
is less susceptible to oxidative damage than the omega-6
series [63]. The peroxide tone theory [64] also contributes
to explain the inhibitory effects of omega-3 fatty acids on
the vascular production of inflammatory molecules, namely,
eicosanoids (via both COX isoforms inhibition), cytokines
[65], and leukocyte adhesion molecules.
From a mechanistic viewpoint, NAD(P)H oxidase is
one of the major contributors to endothelial free radical
production: its inhibition by DHA and (presumably) other
PUFAs might greatly explain the observed effects on ROS
production. Massaro et al. (2006) [66] also reported DHA-
mediated inhibition of IL-1a-inducedROS production, which
would contribute to the anti-inflammatory actions of omega-
3 fatty acids at the endothelial level. Other potential mecha-
nisms of action of LCPUFAswould be that they act as a “sink”
to trap free radicals, hence becoming oxidized themselves
[63].
In vivo situations induce changes in the relative distri-
bution, and proportion of PUFAs in cell membranes and
lipoproteinsmay result inmodifications of their susceptibility
to oxidation, whose extent cannot be easily predicted on
the sole basis of their fatty acid composition. Furthermore,
PUFAs, especially those of the omega-3 series, are precursors
of anti-inflammatory lipid mediators such as protectins,
resolvins, and neuroprotectins [63, 67].
In conclusion, based on evidence showing reduced excre-
tion of lipid peroxidation products, that is, isoprostanes,
after polyunsaturated fatty acid intake and data on ROS
production and direct superoxide removal by LCPUFAs,
mainly those of the omega-3 series, this series of fatty
acid might indirectly act as anti- rather than prooxidant in
vascular endothelial cells, thereby decreasing inflammation
and, in turn, the risk of atherosclerosis [63].
4.1.2. 𝜔-3 Fatty Acids and Inflammatory Signaling. The
inflammatory response clears and fights against infection,
repairing damaged tissue and organ systems, and removing
harmful chemical. Though the net process is protective, the
failure to resolve the inflammation and return the target
tissue to homeostasis can result in disease. Evidence has
provided that dietary 𝜔-3 polyunsaturated fatty acids and
eicosapentaenoic (EPA, 20:5 𝜔-3) and docosahexaenoic acid
(DHA, 22:6 𝜔-3) in particular are important modulators of
inflammatory responses [68].
Dietary intake of 𝜔-3 PUFAs is known to be associated
with the decrease of oxidative and inflammatory markers,
whereas a high 𝜔-6/𝜔-3 PUFA ratio is associated with
increase of inflammation [69]. The fact indicates that PUFAs
might regulate systemic inflammation status.
The metabolites of PUFAs actively participate in cell
signal transduction pathways and to some degree regulate
gene expression. Generally, 𝜔-3 PUFAs produce 3-series
prostaglandins and 5-series leukotrienes by cyclooxygenase-
1 (COX-1) [47]. Increased consumption of 𝜔-3 PUFAs could
consequently inhibit 𝜔-6 PUFA derived prostaglandin syn-
thesis from COX-2. Therefore inhibition of inflammatory
responses, such as COX-2 induction and prostaglandin E2
synthesis, may be effectively involved in the effect of 𝜔-3
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PUFAs and in the difference between 𝜔-3 and 𝜔-6 PUFAs
[70].
The fact that selective COX-2 inhibitors gave satisfactory
relief of symptoms in both osteoarthritis and rheumatoid
patients suggests that eicosanoids participate in the inflam-
matory process of these severe bone/joint diseases. COX-2
and its product PGE2 appear to be a common link between
the two disease states, and since it is possible to regulate the
activity and expression of COX-2, this enzyme is a potential
target for dietary intervention in optimizing bone formation
and controlling bone disease [71].
Inflammatory cytokines (e.g., IL-1, a major player in
rheumatoid arthritis (RA) and osteoarthritis (OA)) are
known to inhibit chondrocyte proliferation and induce
cartilage degradation, therefore part of the response may
be mediated by PGE2. Excessive production of PGE2 is
linked to joint pathology (rheumatoid arthritis), known to
exacerbate inflammatory responses, and results in a net
loss of proteoglycan from articular cartilage [71]. 𝜔-3 PUFA
dietary supplements ranging from 3 to 6 g/day showed a
modest, but rather consistent beneficial effect of these fatty
acids in joint disease. In the same way, the syntheses of
proinflammatory factors IL-1, IL-2, and TNF-𝛼 in cartilage
tissue were suppressed by dietary supplementation with fish
oil containing both EPA and DHA [71, 72].
Themode of 𝜔-3 fatty acid action in RA patients could be
related to eicosanoid biosynthesis. One explanation for this
phenomenon is that the EPA metabolite PGE3 has a higher
proinflammatory effect compared with PGE2 [73]. Lowering
PGE2 in the diseased joint with diets rich in long-chain 𝜔-3
fatty acids could further benefit RA patients by reducing bone
resorption since PGE2 stimulates osteoclast activity, which
results in secondary osteoporosis. Since PGE2 activation of
the IGF-I/IGFBP axis may play an important role in cartilage
biology and collagen and proteoglycan synthesis, dietary fatty
acids may also be important for supporting joint repair.
Further investigations are needed to describe the effects of
nutraceutical fatty acids and the ratio of 𝜔-6/𝜔-3 fatty acids
on cartilage biology, joint disease, and ligament healing since
dietary sources of these fatty acids exert potent effects on
prostanoid biosynthesis in controlling cell activity in these
processes [71].
It has been suggested that dietary supplementation with
LC𝜔-3 PUFA can suppress the production of TNF-𝛼 [73], but
no significant changes in IL-6 and TNF-𝛼 were observed in a
study when subjects received either 2 g, 4 g, or 6 g per day of
Hi DHA (26%DHA and 6% EPA) over 12 weeks [74]. Similar
findings were reported in a study that did not observe any
effect on levels of IL-6 concentrations after supplementation
with 3.4 g per day of LC𝜔-3 PUFA for 6 weeks. Another study
reported that weight loss but not LC 𝜔-3 PUFA influenced a
significant reduction in IL-6 and a nonsignificant reduction
in TNF-𝛼. These authors suggest that as IL-6 is secreted by
adipose tissue, a reduction in fat mass could contribute to a
reduction of IL-6 levels [75].
It has also been reported that DHA has more potent anti-
inflammatory effects than EPA, and that DHA is a key con-
troller of hepatic lipid metabolism and is ultimately involved
in the suppression of lipogenesis which could impact on
weight management. In this way, there are gender difference
in the metabolism of LC 𝜔-3 PUFA with studies showing
significantly higher concentrations of DHA in females com-
pared to males [76, 77].
There is conflicting evidence on the effect of LC𝜔-3 PUFA
on plasma leptin levels, with some studies reporting that EPA
increases leptin levels [66], and others suggesting that LC𝜔-3
PUFA reduces leptin levels [78].
Madsen et al. (2008) [79] reported an increase in levels
of adiponectin in response to diet induced weight loss but
suggest that a reduction in weight of at least 10% is required
to show a signficant increase in levels of adiponectin.
Conflicting findings have also been reported from studies
investigating the effect of diet and/or weight on C-reactive
protein (CRP) levels. One study reported that LC 𝜔-3 PUFA
but not weight loss was associated with a significant reduc-
tion in CRP [80], while another study reported an inverse
association with LC 𝜔-3 PUFA and serum CRP in men [81].
Observational studies support that 𝜔-3 is associated with
lower levels of CRP [82], while randomised control trials have
reported no effect of LC 𝜔-3 PUFA on CRP levels in healthy
people [83]. It has also been suggested that a reduction in
the level of CRP is directly related to a reduction in weight.
However, a significant reduction in the long term requires
a weight loss greater than 10%, and not only differences in
the length of the intervention but also differences in ages of
subjects within the groups and components of the different
diets could influence levels of plasma CRP [73].
4.1.3. 𝜔-3 Fatty Acids and Obesity. Obesity is regulated by
cytokines and endocrine factors that have effects on bone
and calcium absorption; obesity also increases bone fracture
risk. Long-chain omega-3 polyunsaturated fatty acids (LC
𝜔-3 PUFA) are essential nutrients that play a beneficial
role in several pathological processes because of their anti-
inflammatory effects, calcium absorption, andmodulation of
lipids. Omega-3 fatty acids, EPA and DHA predominantly,
have shown preliminary results in animal and human studies
in the treatment and prevention of obesity.
There is controversy about the beneficial effects of supple-
mentation with LC 𝜔-3 PUFA on reducing adiposity. Some
studies have associated 𝜔-3 PUFA with weight loss [84], in
others with a decrease in adipose tissue mass [85], whereas
other studies have shown no effect on adiposity [86]. It has
also been suggested that concentrations of 𝜔-3 are signif-
icantly lower in obese compared to normal weight adults,
adolescents, and children suggesting that high concentrations
of 𝜔-3 in the body inhibit the development of adiposity
or have possibly reduced weight previously gained. In this
respect, if obese individuals are given time to increase levels of
𝜔-3 prior to commencing a reduced energy weight loss diet,
it may result in greater weight reduction [87].
A growing evidence supports that there are gender differ-
ences in the metabolism of 𝜔-3 PUFA. It has been reported
that not only higher levels of DHA and lower levels of EPA are
circulating in serum lipids in females compared to males, but
also females aremore responsive to themetabolism of LC𝜔-3
PUFA compared to males. Other studies have also reported
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that females had a higher percentage of total fatty acids as
DHA in plasma and adipose lipids compared to males [87].
The mechanisms by which LC 𝜔-3 PUFA assist the
reduction of body fat and/or body weight are still being
explored. It has been suggested that 𝜔-3 modulates lipid
metabolism promoting lipolysis and enhancing hepatic fatty
acid oxidation, inhibiting fatty acid synthesis andVLDL (very
low density lipoprotein) secretion. It has been established
that DHA is a key controller of hepatic lipid synthesis, has a
major impact on hepatic lipid metabolism, and is ultimately
involved in the suppression of lipogenesis [88].
It is possible that an extended period of 𝜔-3 intake
during the growth years rather than dietary supplementation
with large doses over a short duration in adults influences
body weight. In this context, several studies have reported a
significantly higher concentration of 𝜔-3 in normal weight
compared to obese individuals but timing and duration of
intake of 𝜔-3 in the individuals is unknown [89].
It is also possible that incorporation of 𝜔-3 LCPUFA
into the adipose tissue is needed for any effects on weight
loss to occur and, despite long-term supplementation in
adults, an increase in the levels of EPA and DHA in adipose
tissue is reportedly modest [86]. As late foetal and early
postnatal life is a highly sensitive period when adipose tissue
expands rapidly [90], this could be a critical opportunity to
improve the balance of fatty acids involved in adipogenesis
and lipogenesis. A study in humans, where mothers received
DHA supplementation from 21 weeks gestation until the
end of the third month of lactation, reported a significant
time-dependent effect of DHA on weight and body mass
index (BMI) reduction in their infants at 21 months [91].
Thus, it would appear that when increasing levels of 𝜔-3
for weight management, gender, age, duration of supple-
mentation, concentration, and ratio of EPA :DHA all require
further consideration.
While there is evidence from a considerable number of
animal studies that LC 𝜔-3 PUFA can reduce body fat, their
impact on body composition in humans is less evident due to
a lack of appropriately designed studies of adequate size and
duration [92].
In human studies it is becoming apparent that an
increased intake of LC 𝜔-3 PUFA by 0.3–3.0 g/day can reduce
body weight and body fat in overweight and obese individ-
uals. The mechanism by which increasing the intake of 𝜔-3
PUFA by such an amount may improve body composition
is most likely altered gene expression favoring increased
fat oxidation in adipose and skeletal muscle tissue and
reduced fat deposition in adipose tissue. Some studies have
reported that an increase in 𝜔-3 PUFA intake within this
dose range might also attenuate postprandial sensations of
hunger, although the majority of studies which have reported
improved body composition have not reported any reduction
in food (i.e., energy) intake. Data from other studies also
support that LC 𝜔-3 PUFA might promote increases in lean
tissue mass, thus potentially increasing metabolic rate and
indirectly assisting with body fat reduction. It might be
possible that the increases in vasodilator function andmuscle
blood flow during exercise resulting from supplementation
with 1.9–5.0 g/day of LC 𝜔-3 PUFA might promote nutrient
disposal by skeletal muscle, thus reducing the availability of
nutrients for lipogenesis and storage in adipose tissue [92].
𝜔-3 PUFA have been shown to affect body composition
and to reduce the accumulation of body fat, thereby affecting
body weight homeostasis. However, in adults, the studies
analyzed [93–95] show no change in body weight by dietary
supplementation with 𝜔-3 PUFA, except for one [96]. The
results do not provide data strong enough to conclude that
𝜔-3 PUFA can modify and particularly reduce body weight.
Marked differences in experimental design, intervention type
and duration, baseline characteristics of the participants
(degree of obesity, associated condition, etc.), attrition rate,
dose of 𝜔-3 PUFA, and EPA/DHA ratio make the results
inconclusive and, in some cases, discordant [97].
An observational study of 124 adults found that obese
individuals had significantly lower plasma 𝜔-3 PUFA con-
centration compared to healthy weight participants. In obese
subjects, there was a significant inverse correlation between
plasma 𝜔-3 PUFA and BMI [98].
Studies in youth report significantly decreased plasma 𝜔-
3 PUFA concentration in overweight compared to healthy
youth; in obese youth plasma 𝜔-3 PUFA is significantly
inversely related to BMI [98].
Randomized controlled trials in humans examining the
relationship between 𝜔-3 supplementation and body com-
position have found conflicting results. This may be due
to differences in study design, the dosage, timing, and
duration of 𝜔-3 PUFA administration, and the use of other
supplements in addition to 𝜔-3 PUFA [99].
Published literature supports evidence for a role of 𝜔-3
PUFAs in body composition. A study of 2-month 𝜔-3 PUFA
supplementation in 26 overweight or obese postmenopausal
women with diabetes found a reduction in body fat mass and
a reduction in adipocyte diameter, though no reduction in
body weight or total energy intake was observed [94]. An
8-week study of 278 overweight adults found that those on
a restricted caloric diet rich in lean or fatty fish or fish oil
had a significant reduction in waist circumference andweight
compared to individuals on a calorie restricted diet, but this
effect was only seen inmen [100]. Participants in this study on
the high 𝜔-3 PUFA diets reported more fullness immediately
after a test meal and more fullness and less hunger 2 hours
postprandial than those on a low 𝜔-3 PUFA diet [101]. This
finding provides a potential role for𝜔-3 in appetite regulation
in humans.
Moreover, different organ systems in the body and various
pathways are involved in appetite, food intake, and energy
homeostasis, and the disruption of these systems leads to
obesity.These include brain structures such as the brain stem,
hypothalamus, and reward pathways, as well as the gastroin-
testinal tract, adipose tissue, and the pancreas. Increasing
evidence suggests that the 𝜔-3 fatty acids EPA and DHA play
an important role in these organ systems and especially in the
central nervous system [99].
While the effects of EPA/DHA on the endocannabinoid
system and on dopaminergic reward systems in the brain
have been described, no animal or human studies have exam-
ined the role of DHA and EPA in modulating these systems
to affect appetite and food intake. As the endocannabinoid
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and mesocorticolimbic pathways play a role in appetite,
energy intake, and obesity, we hypothesize that, in addition to
beneficial effects on metabolism, EPA and DHA regulate the
endocannabinoid and mesocorticolimbic dopamine systems
in humans to decrease appetite, increase satiety, reduce
food intake, and ultimately contribute to prevent or reduce
overweight and obesity [99].
Further studies are necessary to elucidate the effects of
EPA/DHA supplementation on the reward associated with
food intake and appetite, food consumption, weight loss,
and, at the same time, the molecular effects on the function
of the endocannabinoid system and the mesocorticolimbic
system. Studies in humans are especially noteworthy, because
molecular and behavioral changes in animal models may not
correspond to the same effects in humans. In addition, the
interplay between diets of differing composition of essential
fatty acids and effects of EPA/DHAmust be further examined
because the effects of 𝜔-3 PUFAs also depend on the ratio of
𝜔-3 to 𝜔-6 fatty acids, as they are substrates that compete for
some of the same enzymes [99].
Animal and human studies indicate that EPA and DHA
supplementationmay be protective against obesity andmight
reduce weight gain in already obese animals and humans.
There is evidence in animal studies that 𝜔-3 PUFA supple-
mentation canmodulate fat deposition, food intake, and body
weight. Nevertheless, we should use caution when making
inferences to the effects of 𝜔-3 PUFA in humans, because
of possible differences of EPA and DHA supplementation
between animals and humans and because the doses used in
animal studies vary widely and are typically higher than those
considered safe in humans [99].
4.1.4. 𝜔-3 Fatty Acids in Menopause and Aging. The best way
to avoid osteoporosis in women is to build strong bones
in early life by consuming a well-balanced diet (vitamin D,
calcium, 𝜔-6 and 𝜔-3 fatty acids, etc.) and to follow a routine
exercise program pre- and postmenopause.
Although osteoporosis occurs in both women and men,
postmenopausal women have the greatest risk of developing
this disease. Extensive research has been conducted to find a
cure for the disease; however, optimizing bone development
in the young and reducing bone resorption to maintain bone
mass and restore skeletal integrity in the older are still the best
means to control the disease. Direct evidence of any beneficial
effect of dietary 𝜔-3 fatty acids on human osteoporosis is
still lacking. However, experiments using animal and cell
culture models and epidemiological data suggest promising
applications of 𝜔-3 PUFA on this disease [102].
Some studies suggest that using 𝜔-3 fatty acid supple-
ments, which are antagonistic to arachidonic acid (AA) in
the sense of eicosanoid action, could help maintain bone
mineral content after menopause in women. Considering the
results from these ovariectomized rat studies (inhibitory to
bone resorption) and the findings on 𝜔3 fatty acids in bone
modeling (promoting bone formation), it is plausible that
consuming diets rich in 𝜔-3 fatty acids will help to build and
maintain a healthy skeleton in the human [102, 103].
Högström et al. (2007) [50] reported that serum phos-
pholipid levels of 𝜔-3 PUFA and DHA were positively
associated with bone mass density (BMD) in healthy young
men. However, there has been no study investigating the
relationship between tissue fatty acid composition and BMD
in women, and studies on the effect of 𝜔-3 PUFA on bone
health are inconclusive.
There is an available study that demonstrates that tissue
levels of 𝜔-3 PUFA are positively correlated with bone mass
in postmenopausal women. High erythrocyte levels of EPA
+ DHA reduced the risk of osteoporosis in postmenopausal
Korean women [104].
Epidemiologic studies have shown a positive association
between BMD and the intake of n-3 PUFA in older adults
or the intake of fish in postmenopausal women and the
elderly [105]. A cross-sectional study in China also reported
a greater bone mass and lower risk of osteoporosis among
postmenopausal womenwith a higher intake of sea fish [106].
In addition, clinical trials by Tartibian et al. demonstrated
that 1 g/day of 𝜔-3 PUFA supplementation over a period of
24 weeks was effective in reducing chronic inflammation and
increasing BMD in postmenopausal women [107].
Although the mechanism is not known, 𝜔-3 PUFA has
been shown to reduce the formation of prostaglandin E2,
which stimulates bone formation through increased produc-
tion of an insulin-like growth factor, a powerful growth stim-
ulator for bone and muscle 5. 𝜔-3 PUFA has also been shown
to increase calcium absorption and decrease the production
of inflammatory cytokines induced by osteoclastogenesis
[104].
In the female population, postmenopausal individuals are
regarded as more vulnerable to oxidative stress (OS) than
those in reproductive age, because their oxidative balance is
deranged not only by the generally older age but also by a
lower level of 17𝛽-estradiol (E2), believed to act as an antioxi-
dant. Consistently, a considerable amount of in vitro evidence
suggests that ROS could be involved in the pathogenesis
postmenopausal osteoporosis (PO) which is characterized by
increased bone loss and consequent higher risk of fractures
[108]. Further experiments on human osteoclast like cell
lines showing that E2 enhances the intracellular antioxidant
defences suggest that estrogenic skeletal protection occurring
in premenopausal period of female could be attributed, at
least partly, to the opposing activity of these hormones toward
OS development [109].
OS is not itself a characteristic condition of subjects
affected by PO, but that it might influence BMD loss in
womenwhohave already experienced themenopausal transi-
tion, thus increasing the risk of this severe bone degenerative
disease. In other terms it can, therefore, be assumed that
the association between altered hydroperoxide levels and
the selective decline in BMD in postmenopausal women
might reflect an interplay between OS and the menopausal
endocrine changes [109].
Although relevant progress has been achieved in the
understanding of how estrogen deficiency induces bone loss,
the underlying pathogenic mechanisms have proven to be
remarkably complex. One of themechanisms suggested takes
into account the ability of E2 to regulate receptor activator of
nuclear factor-kappa 𝛽 (NF-𝜅𝛽) ligand- (RANKL-) RANK-
osteoprotegerin pathway. RANK along with OS is, in turn,
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potent activators of NF-𝜅𝛽, the osteoclastogenic factor that
regulates osteoclast differentiation and thus bone resorption
and remodelling [108].
Pansini et al. (2008) [110] does not show any significant
correlation between menopause, level of circulating E2, and
markers of OS. Indeed, if E2 has an antioxidant action
against level of systemic oxidative damage (as in the in vitro
inhibition of LDL oxidation), this is usually obtained only at
supraphysiological levels of hormone.
The involvement of oxidative status in the relationship
between estrogen PO is further supported by the finding
that in osteoclast cell lines estrogen upregulate glutathione
peroxidase responsible for the intracellular degradation of
hydrogen peroxide and major antioxidant enzymes of these
cells [109].
Sharif et al. (2010) [111] demonstrated no significant effect
of𝜔-3 fatty acids on bone formationmarkers (osteocalcin and
alkaline phosphatase) in osteoporotic women; it showed sig-
nificant beneficial effects of n-fatty acids on bone resorption
marker (pyridinoline).
𝜔-3 PUFAmay play various roles, possibly affecting bone
formation and resorption through calcium absorption and
production of prostaglandins and cytokines. Epidemiological
studies suggest that the intake of fish or n-3 PUFA is
associated with greater bone mass in both women and men.
Additionally, in clinical trials, supplementation with fish oil
or EPA has been shown to increase bone mineral density
(BMD) in elderly patients and postmenopausal women.
A cohort study that evaluated the effects of omega-3
fatty acids on bone health has investigated the associations
between dietary polyunsaturated fatty acid and fish intakes
and hip bone mineral density (BMD) at baseline (𝑛 = 854)
and changes 4 years later in individuals (𝑛 = 623) with
a mean age of 75 years in the Framingham Osteoporosis.
High intakes (>3 servings/wk) of fish relative to lower intakes
were associated withmaintenance of femoral neck bonemass
density (FN-BMD) in men (dark fish + tuna, dark fish, and
tuna) and in women (dark fish), thus suggesting that fish
consumption may protect against bone loss [105].
5. Conclusion
According to the physiological mechanisms of 𝜔-3 fatty acids
and available data on human studies, the consumption of
𝜔-3 fatty acids might be beneficial on bone metabolism.
Most studies have been conducted in women, but recent
epidemiological data suggest that the effects of dietary fats
on bone health may be particularly strong in men. Some
studies report that bone integrity in both men and women
may benefit from manipulation of the dietary fatty acid
profile, especially the dietary ratio of 𝜔-6/𝜔-3 fatty acids.
Controlled feeding trials are needed in order to demon-
strate convincingly a causal relationship between fatty acids
and bone health, the optimal dose of 𝜔-3 fatty acids, and
the optimal ratio of 𝜔-6/𝜔-3 fatty acids. Lipid intake may
be targets for the development of 𝜔-3 PUFA containing
dietary bioactive agents to down-modulate inflammatory and
immune responses and for the treatment of autoimmune and
chronic inflammatory diseases. Regarding the pathogenesis
of osteoporosis and the interaction between various cells and
mediators, many studies have been conducted to evaluate the
benefit of different therapeutic options, therefore evidence
has been growing on the effects of dietary fatty acids on bone
health.
There is growing evidence that LC 𝜔-3 PUFA can
improve body composition in humans, but some aspects
are still controversial, because the majority of studies have
been of relatively short duration and the magnitude of the
improvements have been modest. Accordingly, there is a
need for long-term studies to determine the relative effects
of EPA and DHA supplementation on body composition
and the feasibility of using LC 𝜔-3 PUFA supplementation
as a strategy to improve body composition in overweight
and obese populations. In several animal studies, 𝜔-3 PUFA
supplementation can modulate fat deposition, food intake,
and body weight. However, we should use caution when
making inferences to the effects of 𝜔-3 PUFA in humans,
because of possible differences in pharmacokinetics of EPA
andDHAsupplementation between animals and humans and
because the doses used in animal studies vary widely and
are typically higher than those considered safe in humans.
Although evidence for a role of 𝜔-3 fatty acids in prevention
of overweight and obesity is just beginning to be accumu-
lated, the various other health benefits and lack of negative
side effects warrant consideration of the need to encourage
dietary changes to increase𝜔-3 PUFA or the use of𝜔-3 PUFA
supplements at the population level. Even if the effect of 𝜔-3
PUFA on overweight and obesity is found to be small, such
changes at the level of the individual can lead to significant
shifts in the distribution of weight in the population.
In conclusion, strong evidences featured in the scientific
literature available to date support the benefits of 𝜔-3 fatty
acids in bone health. Severalmechanismshave beenproposed
(affecting bone formation, bone resorption, serum calcium
and vitamin D, oxidative stress, and inflammatory media-
tors). However, neither the exact benefit nor the exact mech-
anism of action of essential fatty acids has been determined
yet. Therefore, although there are some clinical evidences
linking bone metabolism and dietary lipids, more clinical
trials are necessary to prove whether dietary changes or 𝜔-3
PUFA supplementation play a major role in bone health and
turnover.
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